Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Unicycive Therapeutics Inc (NQ: UNCY )

0.3824 -0.0176 (-4.40%)
Streaming Delayed Price Updated: 12:07 PM EDT, Sep 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Unicycive Therapeutics Inc

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company spearheading efforts to develop effective, safe, and novel treatments for kidney disease to improve patient and caregiver... 
Via Benzinga
Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome
Via Benzinga
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers 
Via News Direct
The Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
Unicycive Therapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical company committed to developing effective and safe treatments for kidney (renal) disease to reduce death rates and improve patients and... 
Via Benzinga
Unicycive: The Company Developing Key Kidney Therapies
by\nJohnny Rice, Benzinga Contributor 
Via News Direct
Unicycive Therapeutics' Geographic Atrophy Candidate Shows Improved Contrast Vision In Animal Studies
Via Benzinga
Unicycive Inks Licensing Pact For Its Kidney Disease Candidate In China
Via Benzinga
Unicycive: The Company Developing Key Kidney Therapies
Doug Jermasek, Executive Vice President, Corporate Strategy for Unicycive Therapeutics, Inc. (NASDAQ: UNCY), was recently interviewed by Benzinga. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Unicycive: This Biotech Company Receives Promising Results From New Trial
Unicycive: This Biotech Company Receives Promising Results From New Trial 
Via News Direct
Unicycive: This Biotech Company Receives Promising Results From New Trial
Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a biotechnology company developing drug candidates currently focused on kidney disease. The innovative treatments may have vast potential outside of the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... 
Via Benzinga
Why Cal-Maine Foods Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket
Gainers Quotient Limited (NASDAQ: QTNT) shares rose 125% to $0.54 in pre-market trading after dropping around 38% on Wednesday. Quotient recently announced the intent to voluntary delist from the... 
Via Benzinga
Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Wednesday. 
Via Benzinga
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Dow Tumbles 150 Points; Crude Oil Falls Sharply
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 150 points on Wednesday. 
Via Benzinga
Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study
Via Benzinga
Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
By David Willey, Benzinga 
Via News Direct
Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?  
Via Benzinga
How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
Via Benzinga
The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.